As a kind of over 10 year aged products, the cone type rubber fender is becoming a trend of quay design, and becoming a new level for quay wall fender design.
1. The energy absorption doubles comparing with the super cell rubber fender with same spec.
2. In the case with similar reaction force and energy absorption, small size cone type fender can substitute relative large supper cell type fender, i. e., 800h cone type fender can substitute 1000H super cell fender, which can reduce the cost of quay wall construction.
3. In the case of oblique berthing (less than a angle of 10° ), the performance can not be reduced, which is preferred to cone model.
4. The frontal frame (steel frame) are installed in front of fenders, which can reduce the surface pressure against vessel hull. The surface can be limited below 25t/m2, which is suitable to large vessel especially.
5. The super high density polyethylene pads are adhered to the frontal frame, which can reduce the friction factor between hull and fender to below 0.2, and can reduce the shear (horizontal force) exerted on fenders when vessel berth, which can prolong the service life of fenders.
6. The frontal frame adopts water-tight structure with high strength and better anti-rust performance.
7. The rubber cone is rarely damaged or impaired, because it never contacts the hull directly.
| Accessories | Purpose |
| Anchor bolt | Mounting the fender on a wharf or a dolphin |
| U anchor | To hang the rubber spring chain |
| Frontal frame | Protecting the hull of vessel |
| Frontal pad | Reducing the friction coefficient and protecting the ship's hull |
| Weight chain | Support of frontal frame |
| Shear chain | Restraining the shearing deflection of the fendering system |
| Tension chain | Resisting stretching of the fender at partial compression |
| Steel mount | Increase fender deflection (equal to 0.5 times the fender height) |
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved Upadacitinib in August 2019 for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, it was additionally approved by the European Commission for the same indication in patients with inadequate response or intolerance to one or more DMARDs and can be used as monotherapy or in combination with methotrexate. Upadacitinib is marketed under the brand name RINVOQâ„¢ for oral administration. It is currently being investigated in several clinical trials assessing its therapeutic effectiveness in other inflammatory diseases, such as psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and atopic dermatitis.
Upadacitinib Cas 1201187-44-1,Upadacitinib Cas 1428243-26-8,Upadacitinib Intermediate Cas 1201187-44-1,Upadacitinib Intermediate Cas 1428243-26-8
 Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com